These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Progress and challenges in the use of latent HIV-1 reactivating agents. Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656 [TBL] [Abstract][Full Text] [Related]
27. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. Shehu-Xhilaga M; Rhodes D; Wightman F; Liu HB; Solomon A; Saleh S; Dear AE; Cameron PU; Lewin SR AIDS; 2009 Sep; 23(15):2047-50. PubMed ID: 19609198 [TBL] [Abstract][Full Text] [Related]
28. Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials. Prince HM Leuk Lymphoma; 2012 Sep; 53(9):1658-9. PubMed ID: 22260164 [No Abstract] [Full Text] [Related]
29. HIV latency reversing agents act through Tat post translational modifications. Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762 [TBL] [Abstract][Full Text] [Related]
30. Panobinostat (Farydak) for multiple myeloma. Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884 [No Abstract] [Full Text] [Related]
31. Panobinostat approved for multiple myeloma. Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326 [No Abstract] [Full Text] [Related]
33. Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins? Vignesh R; Shankar EM EBioMedicine; 2017 Oct; 24():20-21. PubMed ID: 28865747 [No Abstract] [Full Text] [Related]
34. The potential role for romidepsin as a component in early HIV-1 curative efforts. Gunst JD; Tolstrup M; Rasmussen TA; Søgaard OS Expert Rev Anti Infect Ther; 2016; 14(5):447-50. PubMed ID: 26953620 [No Abstract] [Full Text] [Related]
38. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. McMahon DK; Zheng L; Cyktor JC; Aga E; Macatangay BJ; Godfrey C; Para M; Mitsuyasu RT; Hesselgesser J; Dragavon J; Dobrowolski C; Karn J; Acosta EP; Gandhi RT; Mellors JW J Infect Dis; 2021 Aug; 224(4):648-656. PubMed ID: 34398236 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic cancer therapies emerge out of the lab into the limelight. Wolfson W Chem Biol; 2013 Apr; 20(4):455-6. PubMed ID: 23601631 [No Abstract] [Full Text] [Related]
40. Histone deactylase inhibitor SAHA induces a synergistic HIV-1 reactivation by 12-O-tetradecanoylphorbol-13-acetate in latently infected cells. Park SY; Kim KC; Hong KJ; Kim SS; Choi BS Intervirology; 2013; 56(4):242-8. PubMed ID: 23735807 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]